Abstract：
AYA-ALL differs from pediatric ALL in terms of clinical, biological, psychosocial factors and access to care and has an inferior outcome. It is now being recognized that pediatric-inspired protocols are superior to adult protocols for this cohort, but given the lack of randomized trials, several questions remain unanswered.
In this review, we discuss how AYA-ALL is different from the pediatric ALL population, compare AYA-ALL with ALL in middle and older age adults, review the studies that have enrolled the AYA cohort, summarize risk-stratified and response-adapted approaches, describe the biological subtypes, and review the novel agents/approaches under evaluation.
AYA-ALL is a complex and challenging disease that needs multidisciplinary and focused care. Well-designed clinical trials that focus on this cohort are needed to further improve the outcomes.
In this review, we discuss how AYA-ALL is different from the pediatric ALL population, compare AYA-ALL with ALL in middle and older age adults, review the studies that have enrolled the AYA cohort, summarize risk-stratified and response-adapted approaches, describe the biological subtypes, and review the novel agents/approaches under evaluation.
AYA-ALL is a complex and challenging disease that needs multidisciplinary and focused care. Well-designed clinical trials that focus on this cohort are needed to further improve the outcomes.
摘要：
AYA-ALL在临床上与儿科ALL不同，生物，社会心理因素和获得护理的机会，结果较差。现在人们认识到，儿科启发的方案优于成人方案，但是由于缺乏随机试验，几个问题仍然没有答案。
在这篇评论中，我们讨论了AYA-ALL与儿科ALL人群的不同之处，将AYA-ALL与所有中老年人进行比较，回顾参加AYA队列的研究，总结风险分层和反应适应的方法，描述生物亚型，并回顾正在评估的新代理/方法。
AYA-ALL是一种复杂且具有挑战性的疾病，需要多学科和重点治疗。需要针对该队列进行精心设计的临床试验，以进一步改善结果。
在这篇评论中，我们讨论了AYA-ALL与儿科ALL人群的不同之处，将AYA-ALL与所有中老年人进行比较，回顾参加AYA队列的研究，总结风险分层和反应适应的方法，描述生物亚型，并回顾正在评估的新代理/方法。
AYA-ALL是一种复杂且具有挑战性的疾病，需要多学科和重点治疗。需要针对该队列进行精心设计的临床试验，以进一步改善结果。
